CLX · Intrinsic value
Is The Clorox Company (CLX) overvalued or undervalued?
The Clorox Company (CLX) trades at the delayed market price of $84.64 a share. That price already implies revenue growth of 2.3% a year for 5 years. TickerWorth's fair value is $111.03 a share (priced within our range of $72.45 – $164.06). We do not call it over- or undervalued from inside our range.
Model by Miraaj Patel · generated from market data · Updated Oct 19, 2026 · How these pages are made
Is CLX fairly valued?
- Fair value
- $111.03
- Market price
- $84.64
- Upside to fair value
- +31.2%
- Verdict
- Priced within our range of $72.45 – $164.06
Reverse DCF: Today's price implies revenue growth of 2.3% a year for 5 years; our model assumes 1.0% a year on average over the same horizon.
What is CLX's TickerWorth Score?
Scores lower than almost every company we compare it with
Compared with Consumer Defensive companies in US
Its strongest point: a profitable, high-quality business. Its weakest: balance sheet looks stretched.
- Value · 35 of 100
Cheaper than 35% of Consumer Defensive companies in US
- Price vs worth · 64 of 100
- Quality · 64 of 100
More profitable than 64% of Consumer Defensive companies in US
- Financial health · 5 of 100
Financially stronger than 5% of Consumer Defensive companies in US
- Growth · 26 of 100
Growing faster than 26% of Consumer Defensive companies in US
- Momentum · 3 of 100
Outperformed 3% of Consumer Defensive companies in US over the past year
Confidence: High confidence · Scored
Get the Undervalued Company of the Week.
CLX DCF valuation, input by input
TickerWorth's fair value for The Clorox Company (CLX) is $111.03 a share, against the delayed market price of $84.64 (priced within our range of $72.45 – $164.06). We do not call it over- or undervalued from inside our range. It is a model estimate, and every input behind it is sourced below. This is an educational model, not a price target or a recommendation.
Read the full reasoning
One of the lenses behind that blended figure is a discounted-cash-flow model, which on its own values CLX at about $72.45 per share. The rest of this page walks through that DCF — its assumptions, reverse-DCF and discount-rate sensitivity — because it is the auditable anchor of the blend.
The valuation discounts The Clorox Company's projected free cash flows at a weighted-average cost of capital (WACC) of 7.1%, with a long-run terminal growth rate of 2.5%. About 80% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Running the DCF in reverse — solving for the growth the current price already assumes — the market is implying roughly 2.3% annual revenue growth for CLX. Our base case instead compounds to about 1.0% a year over the same forecast, so the market's implied growth is broadly in line with our base case. The reverse-DCF is a quick sanity check: it reframes 'is this stock cheap?' as 'do I believe the growth the price requires?' rather than arguing over a single point estimate of fair value.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, CLX's modeled DCF value ranges from about $33.50 to $204.62 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what The Clorox Company would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of CLX's intrinsic value. Figures update as new filings and prices come in.
Every input behind CLX's DCF
| Input | Value |
|---|---|
| Base-year revenueLive feed — totalRevenue (TTM) | $6,720,000,000 |
| Base EBIT marginComputed — trailing operatingMargins, held roughly flat | 12.9% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | -2% → -0% → 1% → 2% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.3% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 0.54 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesLive feed — sharesOutstanding | 121M |
| Market priceLast known price · as of 2026-10-19 21:01 UTC | $84.64 |
Change CLX's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does The Clorox Company do?
What does it do?
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. It operates in the Household & Personal Products industry (Consumer Defensive sector), headquartered in United States. The company employs roughly 9,200 people.
How does it make money?
The business turns $7.1B in annual revenue into profit. Out of every $100 of sales, about $13 is left as operating profit (operating margin of 12.9%), after a 42% gross margin on the products/services it sells. After all costs, taxes and interest, 8.7% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks stretched: carries heavy debt (22.2× equity), may struggle to cover its short-term bills (0.7× current ratio), and is currently profitable.
Who at CLX filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Rendle Linda J | Director, Chief Executive Officer | Grant / award | $2,360,194.32 | Form 4 for Rendle Linda J (opens sec.gov in a new tab) | |
| Rendle Linda J | Director, Chief Executive Officer | Shares withheld (tax) | $55,643.72 | Form 4 for Rendle Linda J (opens sec.gov in a new tab) | |
| Rendle Linda J | Director, Chief Executive Officer | Shares withheld (tax) | $964,035.49 | Form 4 for Rendle Linda J (opens sec.gov in a new tab) | |
| Peck Laurene E | VP - CAO & Corp Controller | Grant / award | $94,240.52 | Form 4 for Peck Laurene E (opens sec.gov in a new tab) | |
| Peck Laurene E | VP - CAO & Corp Controller | Shares withheld (tax) | $2,412.30 | Form 4 for Peck Laurene E (opens sec.gov in a new tab) | |
| Peck Laurene E | VP - CAO & Corp Controller | Shares withheld (tax) | $27,258.99 | Form 4 for Peck Laurene E (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Common questions
What is CLX's intrinsic value?
TickerWorth's blended fair value for The Clorox Company (CLX) is $111.03 per share, versus a market price of $84.64 (priced within our range of $72.45 – $164.06).
Is CLX overvalued or undervalued?
Priced within our range of $72.45 – $164.06 at $84.64. We don't call CLX overvalued or undervalued from a range. This is an educational estimate, not advice.
What discount rate is used for CLX?
A WACC of 7.1% and a terminal growth rate of 2.5%.
Is The Clorox stock undervalued?
TickerWorth's fair value for The Clorox Company (CLX) is $111.03 against a market price of $84.64. Our read: Priced within our range of $72.45 – $164.06. This is a model estimate, not investment advice.
The Clorox (CLX) DCF valuation and fair value
Our fair value for The Clorox Company (CLX) is $111.03, built on a 7.1% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into The Clorox stock?
Today's price implies revenue growth of 2.3% a year for 5 years; our model assumes 1.0% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $84.64. A model estimate, not investment advice.
The Clorox (CLX) insider trading
The most recent insider filing (SEC Form 4) for The Clorox Company (CLX): Rendle Linda J, Director, Chief Executive Officer, grant / award on 2026-10-05. The latest filings are listed on this page. A disclosure, not a signal to trade.
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.